Metastasis remains the most common cause of death in most cancers, with limited therapies for combating disseminated disease. While the primary tumour microenvironment is an important regulator of cancer progression, it is less well understood how different tissue environments influence metastasis. We analysed tumour-stroma interactions that modulate organ tropism of brain, bone and lung metastasis in xenograft models. We identified a number of potential modulators of site-specific metastasis, including cathepsin S as a regulator of breast-to-brain metastasis. High cathepsin S expression at the primary site correlated with decreased brain metastasis-free survival in breast cancer patients. Both macrophages and tumour cells produce cathepsin S, and only the combined depletion significantly reduced brain metastasis in vivo. Cathepsin S specifically mediates blood-brain barrier transmigration through proteolytic processing of the junctional adhesion molecule, JAM-B. Pharmacological inhibition of cathepsin S significantly reduced experimental brain metastasis, supporting its consideration as a therapeutic target for this disease.
angiogenesis and invasion in the primary tumour 4, 5 . Proteases are organized into highly regulated networks in which their activity is controlled by endogenous inhibitors and interacting partners 5 . The mechanisms by which proteases regulate tumour progression are highly specific, including cleavage of cell-adhesion molecules 6 and processing of growth factors, chemokines and kinases 5,7-10 , and are not only limited to protein degradation and matrix remodelling. We therefore investigated the expression of proteolytic effectors in different metastatic sites to determine whether protease function is important in the rate-limiting steps of extravasation, seeding and outgrowth.
Although previous studies profiling constituent cell types of different tumour microenvironments have been informative in identifying stromal gene signatures, often with prognostic value, they involved manipulation of the tumour to isolate individual cell types, and in most cases stromal cells alone were analysed, without comparative expression data for the tumour cells [11] [12] [13] [14] [15] [16] . Moreover, the focus has largely been on tumour-stroma interactions in the primary tumour, without consideration of the metastatic process. Here, we specifically examine the interplay between cancer cells and the microenvironment in intact xenograft tumours at distinct stages of metastasis using a dual species-specific microarray platform. We focused on three organ sites to which breast cancer commonly metastasizes: the brain, bone and lung [17] [18] [19] . We find that tumour-cell-derived proteases and their inhibitors predominantly undergo stage-specific changes in expression during metastatic seeding and outgrowth in different organs, whereas stromal-derived genes are primarily regulated in a tissuespecific manner. From these analyses, we show that cathepsin S expression is regulated in both a cell-type-specific and stage-dependent manner, and enhances breast-to-brain metastasis.
RESULTS

Differential expression of proteases and protease inhibitors in different metastatic microenvironments
To investigate tumour-stroma interactions in different environments we used a mouse model for organ-specific experimental metastasis (Fig. 1a ). In this model, three different metastatic variants of the human breast cancer cell line MDA-MB-231 (refs 20-22) were injected either intracardially or intravenously into immunocompromised mice, resulting in the development of brain, bone, or lung metastases. Whereas previous studies focused on profiling tumour-cell-specific expression in each of these cell line variants [20] [21] [22] , we have been able to additionally capture the stromal contribution by removing intact whole tumours at distinct stages of metastatic seeding and outgrowth in different organs, followed by expression analyses ( Fig. 1a and Supplementary Fig. 1 ).
We used a platform that enabled simultaneous analysis of tumour and stromal gene expression: the 'HuMu ProtIn' custom array (Hu: human; Mu: murine, Prot: protease and In: inhibitor), which surveys proteases, their endogenous inhibitors and interacting partners 23 . The uniqueness of this microarray is based on the species-specificity of the probe sets, with no cross-reactivity between human and mouse genes 23 . This platform thus allowed us to distinguish between messenger RNA expression changes in the tumour (human) and stromal (mouse) gene space in response to metastatic seeding and outgrowth (early-and late-stage metastases respectively, Supplementary Fig. 1) , with the goal of identifying tumour-stroma interactions that modulate organ-specific metastasis. Each of the metastatic cell variants was transduced with a triple-fusion TK-GFP-Luc imaging vector, enabling non-invasive bioluminescence imaging (BLI) as a read-out of metastatic burden, as previously described 24 . Early-and late-stage metastases in each organ site were collected on the basis of BLI output, as described in the Methods, corresponding to micrometastatic and macrometastatic disease respectively.
Principal component analysis was used to evaluate global trends in proteolytic network expression across tissue and stage for both tumour cells and stromal cells ( Fig. 1b ). Analysis of tumour-cell-specific gene expression revealed pronounced changes between early-and late-stage metastases across all three organs. Meanwhile, stromal genes were differentially expressed between early-and late-stage metastases in a tissue-dependent manner. The brain and bone stroma showed the most robust changes in gene expression as metastases progressed. Across all tissues, there were few changes in gene expression between the normal tissue (that is non-tumour burdened), and the stroma of early metastases (brain, bone = 0 genes, lung = 3 genes, Supplementary Table 1a ). This could reflect the relatively low disease burden at the early stages, resulting in a minimal impact on the organ as a whole. Alternatively, expression changes in proteolytic genes in the stroma may not be as important in the earliest stages of metastatic extravasation and seeding, possibly owing to a predominant role for tumour-supplied proteases or non-protease factors in the stroma.
Differential gene expression analyses revealed that many genes changed in tumour cells in the brain, bone and lung (242, 241 and 245 genes respectively) between early-and late-stage metastases ( Fig. 1c and Supplementary Table 1b-d). By comparison, there were fewer stage-specific differentially expressed genes identified in the brain and bone stroma (40 and 44 genes respectively), and only one differentially expressed gene, haptoglobin, in the lung stroma ( Fig. 1d and Supplementary Table 1e -g). A substantial proportion of tumourderived genes were shared across all three metastatic sites (176 genes, Supplementary Fig. 2a ), whereas few stromal genes were shared across >1 metastatic site (10 genes, Supplementary Fig. 2b ). Rather, there were multiple tissue-specific proteases and inhibitors in the brain, bone and lung stroma ( Supplementary Fig. 2c ). Quantitative real-time PCR (qPCR) confirmed tissue-specific enrichment of representative candidates for each organ in normal tissue, and early-and latestage metastases ( Supplementary Fig. 2d ). Representative proteases and protease inhibitors that exhibited stage-specific gene expression changes between early and late metastases were validated using immunostaining ( Fig. 2a-e ) and qPCR ( Supplementary Fig. 3a-e ). We also validated several genes identified in lung metastasis xenografts ( Supplementary Table 1a ) in the immunocompetent MMTV-PyMT model of breast-to-lung metastasis ( Supplementary Fig. 3f ,g).
We next examined whether expression changes in stromal cells in organ-specific metastases are a general response to tumour cell colonization of the respective tissue, or whether they are specific to the metastatic cell variant used. In the models used here, bone metastases occasionally develop in animals inoculated with the brainmetastatic (Br-M) variant, and conversely brain metastases can be observed in mice inoculated with bone-metastatic (Bo-M) cells. This allowed us to compare stromal and tumour gene expression in the 'matched' (Br-M to brain, Bo-M to bone) and 'mismatched' (Br-M to bone, Bo-M to brain) samples. Interestingly, for the genes tested, we found that stromal expression changes depend on tumourstroma interactions specific to the metastatic tumour cell variant ( Supplementary Fig. 3a,b ). In contrast, tumour gene expression in different metastatic variants responds to the same microenvironment in a similar manner, suggesting an important effect of the stroma on the tumour gene expression program ( Supplementary Fig. 3c,d ).
Cathepsin S is negatively associated with metastasis-free survival in patients with brain metastasis Whereas previous analyses have identified genes associated with site-specific metastases, few studies have uncovered genes that are concordantly or discordantly expressed in tumour cells and stroma. We therefore took advantage of the species specificity of the HuMu arrays to separately profile stroma-and tumour-derived genes in cross-species analyses. We identified genes for which both human and mouse homologues were significantly altered in each metastatic respectively of the variance in the tumour gene space, and 90.83% and 4.06% in the stromal gene space. This analysis revealed variation in tumour gene expression that was predominantly associated with differences between early-and late-stage metastasis. Meanwhile, variation in the stroma was associated with both stage and tissue. Dotted ellipses were drawn manually to indicate related data points within stage or organ. (c,d) Heat maps of tumour-(c) and stroma-(d) derived genes that were differentially expressed between early and late metastases across different organ sites. The lung stroma did not show extensive differences between early and late stages ( Supplementary Table 1g ). site ( Fig. 3a and Supplementary Fig. 4a,b ). Cathepsin S showed an intriguing expression pattern: while tumour-derived cathepsin S was high in early brain metastases and decreased in late-stage metastases, stromal cathepsin S exhibited the inverse pattern, with higher expression in late-stage brain metastases versus early-stage. qPCR using species-specific probes for cathepsin S confirmed these data in an independent sample set ( Fig. 3b ). To distinguish between the cellular sources of cathepsin S, we will refer to tumour/human CTSS in capitals, and stromal/mouse Ctss in lower-case. We investigated whether there were any associations between CTSS expression at the primary site and organ-specific metastasis-free survival (MFS) using a data set of locally advanced primary breast cancer with clinical annotation 20 . Patients were separated into three equal tertiles of low, medium and high CTSS expression as described in the Methods. Kaplan-Meier analysis was used to assess MFS for brain, bone and lung. Interestingly, the high CTSS expression group was associated with decreased MFS only for the brain, and not bone or lung (Fig. 3c ). This was further evident in a complementary Cox proportional hazards model analysis ( Supplementary Fig. 4c ).
We similarly determined whether other tumour genes that were differentially expressed in the experimental model ( Fig. 1c ) were associated with differences in patient survival (Supplementary Table 2 ). In addition to CTSS, 26 other genes were significantly associated with brain MFS. Of these, 23 genes were negatively associated with brain MFS ( Supplementary Fig. 4c and Table 2a ). Thirty genes were associated with bone MFS, of which 6 genes were negatively associated ( Supplementary Fig. 4d and Table 2b ). Fifty-nine genes were associated with lung MFS, of which 45 genes were negatively associated Independent validation of differentially expressed genes in experimental brain, bone and lung metastases. (a-e) Representative images of control (non-tumour-burdened) tissue and early-and late-stage sitespecific metastases (classified by BLI intensity as in Supplementary Fig. 1 ; n = 3 samples for each stage and tissue) showing immunofluorescence staining of tumour-and stromal-derived proteases and protease inhibitors exhibiting stage-dependent expression changes in the HuMu ProtIn array. (a) Brain sections were stained with antibodies against the protease CTSZ (red) and the protease inhibitor TIMP2 (red) as representative candidates that were differentially expressed in tumour cells. (b) Bone sections were stained with antibodies against the protease ADAM17 (red) and the protease inhibitor SERPINB10 (red) to represent differentially expressed candidates in tumour cells in bone metastases. (c) Lung sections were stained with antibodies against the protease MMP24 (red) and the protease inhibitor SERPINE2 (red) to confirm stage-differential expression in tumour cells in lung metastases. (d) Staining for the stromal-derived protease Bace1 (red) and the protease inhibitor Timp1 (red) confirmed stage-specific expression changes in GFAP + astrocytes (white). (e) Staining for the protease Ctse (red) and the protease inhibitor Csta (red) confirmed stage-specific stromal changes in bone metastasis. CD68 + macrophages (white) were identified as the predominant source for Csta in bone metastases. All sections were stained with GFP (green) to visualize tumour cells and DAPI as a nuclear counter stain. Scale bars, 50 µm.
( Supplementary Fig. 4e and Table 2c ). Although tumour cells underwent largely congruent changes in gene expression from early-to latestage metastases across the three organs ( Supplementary Fig. 2a ), only 20 of these genes were significantly associated with MFS at multiple sites, whereas most genes were associated with tissue-specific MFS ( Supplementary Fig. 4f and Table 2a -c).
CST7 in brain metastasis, and CTSS and SERPINA3 in bone metastasis, were the only genes that showed similar stage-dependent and cell-type-specific expression changes to CTSS in brain metastasis ( Fig. 3a and Supplementary Fig. 4a ). Given that we did not observe an association of CTSS expression with patient bone MFS, and neither CST7 nor SERPINA3 expression associated with brain and bone MFS respectively ( Supplementary Fig. 4a ,b), we chose to further investigate the potential role of cathepsin S specifically in brain metastasis, a function not previously ascribed to this protease, or any cathepsin family member. Figure 3 Cathepsin S shows highly regulated stage-and cell-type-specific expression changes in experimental brain metastases, and that cathepsin S expression in primary breast tumours is inversely correlated with brain MFS in patients. (a) Cross-species scatter plot shows log-fold expression changes in the tumour and stromal gene space in early-versus late-stage brain metastases. Differentially expressed genes in either the stromal (mouse) or tumour (human) gene space are shown in pink or black respectively. Genes that are differentially expressed in both the stromal and tumour gene space are shown in purple. Grey dots represent homologues with insufficient fold change as detailed in the Methods. Horizontal and vertical lines denote fold-change cutoff for significance. (b) Expression of tumour-derived and stromal-derived cathepsin S (CTSS or Ctss respectively) in Br-M control (Ctrl; n = 11 samples) cell line, normal brain (n = 12 mice), and brain metastases (classified by BLI intensity; n = 16 mice for early-stage and n = 17 mice for late-stage metastases). mRNA expression is depicted relative to Ctrl for CTSS and relative to normal brain for Ctss. All assays were performed in triplicate and gene expression was normalized to Ubc (stromal genes), B2M (tumour-cell-derived genes). (c) MFS for breast cancer patients (GSE12276 data set) based on low, medium and high CTSS expression at the primary site. (d) Representative images of matched primary breast cancer and brain metastasis patient samples stained for CTSS (red) and CD68 (macrophages; white), or pan-cytokeratin (CK, tumour cells; green), and DAPI (nuclei; blue). Images are representative of specimens quantified in e. Scale bars, 50 µm. (e) Quantification of proportions of tumour cells and macrophages, presented as the percentage of total DAPI + cells, in matched primary breast cancer (n = 6 samples) and brain metastases (n = 6 samples).
(f) Quantification of the CTSS index as a measure of relative CTSS levels in tumour cells and macrophages. Data are presented as bars + s.e.m. or as box plots (boxes: values between the 25th and 75th percentile; whiskers: minimum and maximum values; horizontal line: median). P values were obtained using two-tailed unpaired t-test for b and a log-rank test for c. * * P < 0.01, and * * * P < 0.001.
The patient expression data above were derived from wholetumour samples, thus precluding cell-type-specific expression analyses. We therefore stained a set of patient samples of brain metastases, with matched primary breast tumours in a subset of cases (Supplementary Table 3 ). Across all samples (breast cancer and brain metastases), we found the main cell types contributing to the tumour mass were cytokeratin (CK) + tumour cells and CD68 + macrophages, with a minor fraction representing CK − CD68 − cells (Fig. 3d,e and Supplementary  Fig. 5a-d ). CTSS levels were highest in CD68 + macrophages, with expression also in CK + tumour cells, albeit at lower levels than in macrophages, in both primary tumours and matched brain metastases (Fig. 3d,f and Supplementary Fig. 5a ,b,e). CTSS expression in tumour cells was observed in all molecular subtypes of breast cancer analysed ( Fig. 3d,f and Supplementary Fig. 5a ,b,e and Table 3 ).
Combined depletion of cathepsin S in tumour and stromal cells reduces experimental brain metastasis
We investigated the stromal cell source of Ctss in the experimental brain metastasis model. Seeding and outgrowth of brain metastasis induced a stromal response characterized by accumulation of astrocytes and macrophages/microglia in metastatic lesions (Supplementary Fig. 1d ). Detection of cathepsin S using an antibody that recognizes both mouse and human homologues, in combination with cell-type-specific markers, identified macrophages as the predominant stromal cell type expressing Ctss in brain metastases and normal brain ( Fig. 4a ). We observed a gradual increase of Ctss expression in Iba1 + macrophages from normal brain to early-and late-stage metastases. CTSS expression was also detectable in tumour cells, although at lower levels than in macrophages, mirroring the patient analyses. At late stages, CTSS expression was undetectable in most tumour cells. We found a similar expression pattern in an immunocompetent brain metastasis model ( Supplementary Fig. 3g ). These data confirm the stage-and cell-type-dependent expression changes at the protein level as predicted by the HuMu array.
Given the reciprocal, cell-type-specific expression pattern of cathepsin S, we sought to investigate whether tumour and stromal sources play important, perhaps complementary roles in the seeding and outgrowth of experimental brain metastases. To address this, we performed short hairpin (sh)-RNA-mediated CTSS knockdown (KD) in Br-M cells, achieving a 90% reduction of CTSS expression at both the mRNA and protein level, and a corresponding reduction in secreted CTSS protein ( Supplementary Fig. 6a -c). CTSS KD did not alter tumour cell proliferation in culture ( Supplementary  Fig. 6d ). After backcrossing Ctss knockout (KO) mice 25 into the athymic/nude background, we generated four experimental groups (shown in Fig. 4b ), to analyse the effects of targeting tumour or stromal cathepsin S alone, or in combination, compared with the control group. Interestingly, only the combined removal of tumour and stromal cathepsin S significantly reduced brain metastasis incidence ( Fig. 4b , Control (Ctrl); Ctss wild-type (WT) versus CTSS KD; Ctss KO), whereas targeting either source separately had no effect. A separate cohort of mice for all four experimental groups was aged until day 35 post-tumour cell injection, which was selected as the time point by which all mice in the control group had developed brain metastases ( Fig. 4b ). Brain imaging at this endpoint revealed a 64% decrease in BLI signal only in the CTSS KD; Ctss KO group ( Fig. 4c,d ). Together, these results indicate that while there is a stagedependency to cell-type-specific cathepsin S expression, contributions from both cellular sources are apparently required to regulate brain metastasis.
Cathepsin S promotes transmigration of the BBB by metastatic cells
To gain insights into the mechanisms underlying impaired metastatic seeding and/or outgrowth specifically in the CTSS KD; Ctss KO group, we next analysed multiple tumorigenic processes at day 35. We found that the size and proliferation rate of brain metastases in CTSS KD; Ctss KO mice were significantly lower than any of the other groups ( Fig. 4c-e ), whereas there were no differences in apoptosis ( Supplementary Fig. 6e ). The small lesions that did develop in the CTSS KD; Ctss KO mice were closely apposed to the vasculature, with most tumour cells being only 1 cell diameter from the vessel, and a pronounced reduction in growth away from blood vessels ( Fig. 5a,b) . Similarly, analysis of the GFP + tumour cell area relative to the CD34 + blood vessel area confirmed this reduction ( Supplementary  Fig. 6f ). Critically, Ctss deletion did not alter blood vessel density or permeability in the normal brain of non-tumour-bearing animals ( Supplementary Fig. 6g ,h). These results are suggestive of either a potential defect in seeding of brain metastatic cells in the earliest stages, or a subsequent impairment in colonization, or perhaps deficiencies in both processes.
To investigate these possibilities, we assessed metastatic seeding across the four experimental groups. We examined the earliest steps of brain metastatic cell homing and survival 26 , specifically the first 48 h. We found that 24 h after CTSS KD tumour cell injection, BLI signal was reduced in both WT and Ctss KO mice, with a further decrease in BLI signal at 48 h only in the CTSS KD; Ctss KO group ( Fig. 6a,b) . Similarly, analysis of the proportion of viable tumour cells still within the blood vessel lumen (intravascular), in the process of extravasating, or fully extravascular, revealed significant differences in the CTSS KD; WT group at 24 h, and in the CTSS KD; Ctss KO group at both 24 h and 48 h ( Fig. 6c ).
Given the initial reduction in tumour cell extravasation in CTSS KD; Ctss WT mice ( Fig. 6a ,c), although the incidence of detectable brain metastasis was ultimately not affected ( Fig. 4b ), we assessed subsequent metastatic colony outgrowth. While there was an initial trend towards delayed growth in the CTSS KD; Ctss WT cohort, brain metastases ultimately grew to the same extent as controls ( Supplementary Fig. 7a ). In contrast, tumour growth kinetics in the CTSS KD; Ctss KO group did not recover over the same period ( Supplementary Fig. 7a ). This suggests that tumour-and stromalderived cathepsin S show some functional redundancy during seeding and outgrowth, and the impact of each cellular source is most likely regulated by differential expression levels at distinct stages. In addition, tumour-cell-derived CTSS may be important for the initial steps of BBB transmigration and extravasation into the brain, whereas stromal-supplied Ctss is subsequently involved in supporting tumour cell survival to successfully form brain micrometastases, and only their combined depletion impairs both metastatic seeding and outgrowth. A similar finding was reported in a colorectal carcinoma model, where depletion of both tumour and stromal cathepsin S was required to slow tumour growth 27 . Luminescence Figure 4 Macrophages are the predominant source of stromal-derived cathepsin S and only combined depletion of tumour-and stromal-derived cathepsin S reduces experimental brain metastasis. (a) Representative images of normal brain, early-and late-stage brain metastasis (classified by BLI intensity) co-stained for Ctss/CTSS (red) and GFP (tumour cells; green) or Iba1 (macrophages/microglia; white). Tumour-cell-derived CTSS is indicated by the arrowhead and macrophage-derived Ctss is indicated by the arrow. Images are representative of 5 independent specimens for each stage. (b) Kaplan-Meier curve shows the percentage of brain metastasis-free animals in the four experimental groups indicated in the table. Ctrl; Ctss WT (n = 21 mice), CTSS KD; Ctss WT (n = 16 mice), Ctrl; Ctss KO (n = 22 mice), and CTSS KD; Ctss KO (n = 12 mice). 
Cathepsin S promotes BBB transmigration through junctional protein cleavage
The BBB is a selective barrier between the systemic circulation and the brain, which is formed by specialized endothelial cells, pericytes and astrocytes 28 . Although the BBB restricts the entry of most macromolecules, it is not an impenetrable barrier to transmigration of metastasizing cancer cells. We therefore examined the potential role of tumour-cell-supplied CTSS in BBB penetration, by using an in vitro BBB assay 29 . We performed genetic or pharmacological depletion of CTSS in Br-M cells through shRNA-mediated KD or a cathepsin S-specific inhibitor VBY-999 respectively, which did not affect Br-M cell viability ( Supplementary Fig. 8a ). CTSS depletion did not affect the ability of Br-M cells to cross a BBB formed by human umbilical endothelial vein cells (HUVECs) and astrocytes ( Supplementary Fig. 8b) . In contrast, when human brain microvascular endothelial cells (HBMECs) were used instead of HUVECs, this presented a stronger barrier to Br-M transmigration, which was impaired by 55-65% through genetic or pharmacological depletion of CTSS respectively (Fig. 6d ). HBMEC monolayers (without astrocytes) also significantly decreased CTSS KD Br-M cell transmigration ( Supplementary Fig. 8b ), whereas transmigration across HUVECs or astrocytes alone was not altered by CTSS depletion ( Supplementary Fig. 8b ).
Tight and adherens junctions between adjacent cells are critical for maintaining BBB integrity, and are composed of different proteins including junctional adhesion molecules (JAMs), occludin, claudins and cadherins 28, 30, 31 . Therefore, we investigated whether any of these proteins represented potential CTSS substrates. We performed biochemical cleavage assays using recombinant CTSS and recombinant proteins for each of the potential substrates, under similar conditions to those previously reported for E-cadherin cleavage by CTSS (ref. 6) . CTSS efficiently cleaved the JAM family members JAM-A, -B and -C at pH 4.5, the acidic pH of the lysosome, and maintained robust cleavage of JAM-B specifically at pH 6.0, the acidified pericellular pH measured in solid tumours 32 . Importantly, cathepsin S retains activity at neutral pH (ref. 33) . JAM cleavage was inhibited by VBY-999 in all cases (Fig. 7a ). Occludin and claudin (CLDN)-3 were also cleaved by CTSS, whereas CLDN5 and the adherens junction proteins CD31 and CDH5 (VE-cadherin) were unaffected (Fig. 7a ). We examined expression of these genes in HBMECs and HUVECs, and found that only JAM-B was significantly higher in HBMECs (Fig. 7b ). Tissuespecific enrichment of junctional protein genes was confirmed by querying published data sets 34 (Supplementary Fig. 8c ). Staining of several junctional proteins further revealed tissue-specific expression for Jam-B, which was detectable only in brain, and not bone or lung, whereas occludin and Cldn3 showed a broader expression pattern (Fig. 7c) .
As the effects of CTSS depletion or inhibition on Br-M transmigration were observed only when HBMECs were used in the BBB assay, and given the organ-specificity of Jam-B expression ( Fig. 7c ), we reasoned that JAM-B might be the most relevant substrate in this context. We aimed to identify the putative cleavage location for CTSS in JAM-B. We compared fragment sizes of each cleavage product that was detectable with JAM-A, -B or -C specific antibodies to fragments that contain the immunoglobulin (Ig)G1 domain, which is linked to recombinant JAM proteins ( Supplementary Fig. 8d ). The molecular weight of JAM cleavage products and pH dependence of JAM processing by CTSS suggests that all 3 family members share a similar but not fully conserved CTSS cleavage site that is localized close to the transmembrane domain. Alignment of the amino-acid sequence of the JAM family members identified the putative cleavage site for CTSS ( Supplementary Fig. 8e ), which is consistent with CTSS specificity preferences previously identified in biochemical studies [35] [36] [37] . Cleavage in this region probably leads to shedding of the JAM extracellular domain, thereby disrupting cell-cell adhesion. We performed cell-based assays to determine whether tumour-cell-secreted CTSS mediates removal of JAM-B from the HBMEC surface ( Fig. 7d ). Indeed, incubation of HBMECs with Br-M cell-conditioned media led to a CTSS-mediated accumulation of JAM-B in HBMEC-conditioned media after 2-4 h. The effect was decreased by addition of VBY-999 ( Fig. 7e and Supplementary Fig. 8f ).
These results are consistent with impaired BBB transmigration in vitro and in vivo when CTSS is targeted, as CTSS-mediated cleavage of the JAM-B extracellular domain would be expected to disrupt tight junction integrity, thereby allowing tumour cells to breach the BBB.
Cathepsin S inhibition reduces experimental brain metastasis formation
We next examined whether pharmacological inhibition of cathepsin S reduced metastatic seeding and colonization in a preclinical prevention trial (Fig. 8a) . Mice were treated with VBY-999 for 2 days to inhibit cathepsin S activity before Br-M cell inoculation, and were then continuously treated with VBY-999 until the trial endpoint of 35 days post-tumour cell inoculation. Pharmacokinetic analysis showed that VBY-999 levels in the plasma were significantly above the required concentration for target inhibition at the time of Br-M cell inoculation and confirmed that VBY-999 efficiently crosses the BBB with stable concentrations in the brain Supplementary Fig. 9 . throughout the trial (Fig. 8b) . Interestingly, BLI signal was reduced by 65-77% at different time points during the trial and at the 35 day endpoint (Fig. 8c,d) .
Initiation of VBY-999 treatment in fully established, end-stage brain metastases did not alter tumour burden ( Supplementary  Fig. 7b,c) , indicating that targeting this enzyme is most critical in seeding and early outgrowth. We investigated the organ specificity of cathepsin S inhibition by assessing bone metastasis in prevention trials, using two different approaches. First, as bone and spine metastases can develop in the Br-M model, we assessed whether these lesions were affected by VBY-999. There was no significant difference between the treatment groups, which was supported by the finding that genetic depletion of cathepsin S did not affect bone metastasis formation ( Supplementary Fig. 7d,e ). Similarly, a VBY-999 prevention trial specifically in the bone metastasis model showed no change in BLI output or development of osteolytic metastases (Fig. 8e,f and Supplementary Fig. 7f ). These data are consistent with our finding that CTSS expression levels in patients correlated only with brain MFS, and not bone MFS. In sum, cathepsin S inhibition is efficient in substantially and specifically reducing brain metastasis if cathepsin S activity is blocked throughout the disease course.
DISCUSSION
Here we identify a brain-metastasis-promoting role for cathepsin S. Using gene expression screens of distinct metastatic microenvironments in animal models, and analyses of patient samples, we uncovered a specific association between high cathepsin S levels and the development of brain metastases. Interestingly, cathepsin S was regulated in both a cell-type-specific and stage-dependent manner, with high expression in tumour cells in early-stage metastases, which is subsequently downregulated concomitant with increased macrophage-specific expression in late-stage lesions. This pattern of expression shares intriguing similarities with lung metastatic niche development, whereby tenascin C (TNC) is initially provided by the tumour cells to support extravasation into the lung. TNC production later switches to infiltrating stromal cells as lung metastases expand 38 . Cathepsin S also shows cell-type-specific expression in normal tissues, and is predominantly produced by immune and stromal cells 6, 39, 40 . Induction of cathepsin S expression in tumour cells of epithelial origin may indicate a type of 'leukocytic mimicry' whereby metastatic tumour cells could implement immune-cell-like expression programs that enhance mobilization and cell motility. Indeed, similarities between the behaviour of metastatic tumour cells and leukocytes have been noted 41 , which could be particularly advantageous during BBB transmigration 2 .
Considering that extravasation into the brain parenchyma is a rate-limiting step in brain metastasis 30, 42, 43 , we further investigated the contribution of cathepsin S to this specific stage. We identified JAM-B cleavage by cathepsin S as an important mechanism by which BBB transmigration of Br-M cells is enhanced. Consistently, genetic or pharmacological targeting of cathepsin S significantly impaired experimental brain metastasis. We found that both tumour-and stroma-derived cathepsin S are important for metastatic seeding and outgrowth, and infer that this relates to a requirement for high levels of the enzyme overall, rather than distinct functions in these two cell types. Thus, although the levels of tumour CTSS are highest at the step of metastatic cell extravasation, there is nonetheless stromal Ctss already expressed at this stage, albeit at much lower levels than in later stages. Similarly, while stromal cells become the predominant source of cathepsin S during colonization, there is still some tumour CTSS present. Therefore, both sources need to be depleted, otherwise there is some degree of functional compensation from the cell type that is not targeted. Given that our analysis of breast cancer patients revealed a significant association between high cathepsin S levels in the primary site and reduced brain MFS, it may be instructive to specifically consider this patient population for any future therapeutic intervention to reduce brain metastasis by cathepsin S inhibition.
The proteolytic gene expression screens performed herein resulted in the identification of numerous differentially expressed genes that are regulated in a stage-or tissue-specific manner in different metastatic microenvironments. By querying whether expression of these genes in primary breast cancer patients was associated with MFS in brain, bone or lung, we were able to apply an additional filter that allowed subsequent restriction of the gene lists to only those that showed a significant correlation with survival, which represent interesting targets for future investigation. Moreover, determining expression levels of these genes at the primary site may be useful as prognostic markers to evaluate the risk for patients to develop tissue-specific metastasis. As such, the identification of proteases in different metastatic microenvironments, many of which can be pharmacologically inhibited [45] [46] [47] [48] [49] , reveals an abundance of potential targets for metastatic disease.
METHODS
Methods and any associated references are available in the online version of the paper.
Note: Supplementary Information is available in the online version of the paper METHODS Mice. All animal studies were approved by the Institutional Animal Care and Use Committee of Memorial Sloan-Kettering Cancer Center (MSKCC). Athymic/nude mice were purchased from NCI Frederick or bred within the MSKCC animal facility. The cathepsin S KO mouse line (Ctss KO) was generated as described previously 25 and backcrossed for 6 generations to the athymic/nude background. NOD/SCID mice were purchased from Charles River Laboratories. MMTV-PyMT (ref. 50) immunocompetent transgenic mice (FVB/n) were bred within the MSKCC animal facility.
Cell lines. Brain-(Br-M), bone-(Bo-M) and lung-(Lu-M) metastatic variants [20] [21] [22] of the human breast cancer cell line MDA-MB-231 (denoted 'parental') were provided by J.M. and labelled with a triple-imaging vector (TK-GFP-Luc; TGL; ref. 24) to allow for non-invasive in vivo imaging of tumour growth over time. The MDA-MB-231 variants were cultured in DMEM + 10% FBS. Mouse Br-M variants were derived from the TS1 cell line 51 , which was previously isolated from a MMTV-PyMT mammary tumour, through sequential rounds of in vitro and in vivo selection for homing to the brain. These are denoted PyMT-BrM cells. Human umbilical vein endothelial cells (HUVECs) were purchased from the ATCC. Human brain microvascular endothelial cells (HBMECs) and human astrocytes (HA) were purchased from Sciencell. HUVECs and HBMECs were cultured on gelatin-coated cell culture dishes, and HA on poly-L-lysine-coated cell culture dishes in endothelial cell media (ECM, Sciencell) + 10% FBS supplemented with endothelial cell growth factors (ECGF).
Generation of experimental brain, bone and lung metastases. For brain and
bone metastasis generation in xenografted mice, 1 × 10 4 brain-metastatic cells (Br-M) or 1 × 10 5 bone-metastatic cells (Bo-M) were inoculated into the left cardiac ventricle of 6-8-week-old female athymic/nude mice. For lung metastasis generation, 1 × 10 5 lung-metastatic cells (Lu-M) were injected into the lateral tail vein of 6-8-week-old female NOD/SCID mice. For brain metastasis generation in immunocompetent mice, 1 × 10 5 PyMT-BrM cells were inoculated into the left cardiac ventricle of 6-8-week-old female FVB/n mice. Early-and late-stage metastases were defined by bioluminescence intensity (BLI) at the time of tissue collection for samples used in the microarray analysis and the independent sample set used for validation. Brain metastases that had a BLI output between 4.3 × 10 6 and 4.2 × 10 7 photons s −1 were classified as early-stage metastases and were collected between 3-4 weeks after tumour cell inoculation. Late-stage brain metastases had a BLI output between 1.6 × 10 8 and 6.4 × 10 8 photons s −1 and were collected between 5-8 weeks after tumour cell inoculation. Histological and morphometric analyses of these different stages showed that early-stage brain metastases are comprised of clusters of ∼50-200 cells, and can be considered similar to 'micrometastases' , and late-stage metastases consist of clusters of ∼5,000-15,000 cells, corresponding to 'macrometastases' . Representative images of the different stages are shown in Supplementary Fig. 1d . Early-stage bone metastases were defined by a BLI intensity that ranged between 6.3 × 10 6 and 1.1 × 10 8 photons s −1 and were collected 3 weeks after tumour cell inoculation. Late-stage bone metastases showed a minimal BLI intensity of 8 × 10 8 photons s −1 and a maximal BLI intensity of 2.5 × 10 9 photons s −1 and were collected 5 weeks after tumour cell inoculation. Histological and morphometric analyses of bone metastases showed that earlystage lesions are comprised of clusters of ∼50-200 cells, and late-stage metastatic clusters consist of ∼2,000-10,000 cells. Representative images of the different stages are shown in Supplementary Fig. 1e . The generation of 'mismatched' samples (Br-M in bone or Bo-M in brain) followed the same criteria for early-and latestage metastasis. For the experiments shown in Supplementary Fig. 3a -e, stromalderived candidates were chosen to represent genes that show expression changes in an organ-specific manner (see Supplementary Fig. 2b and Table 1e -g). Tumourderived genes were selected to represent genes with expression changes confined to only one organ (see Supplementary Fig. 2a and Table 1b-d) . Early-stage lung metastases were collected 48 h after tumour cell inoculation. The BLI intensity at this time point ranged between 2.1 × 10 6 and 1.7 × 10 7 photons s −1 . Latestage lung metastases were collected 5 weeks after tumour cell inoculation with an average BLI intensity between 8.1 × 10 8 and 3 × 10 9 photons s −1 . Histological and morphometric analyses of lung metastases showed that early-stage lesions are comprised of cells diffusely present throughout the lung (∼2,000-4,000 cells per sectional plane, per entire lung), and late-stage metastatic clusters consist of ∼1,000-5,000 cells. Representative images of the different stages are shown in Supplementary Fig. 1f . Late-stage lung metastases from the spontaneous MMTV-PyMT breast-to-lung metastasis model were collected from 14-week-old female PyMT mice.
For tissue isolation, mice were anaesthetized with 10 mg ml −1 ketamine; 1 mg ml −1 xylazine and retro-orbitally injected with 15 mg ml −1 luciferin. Mice were then intracardially perfused with PBS. Tumour-burdened tissue was identified by the presence of BLI signal for brain and bone metastases. For lung metastases, part of the left lung lobe was collected. Snap-frozen samples were collected for RNA and protein isolation and tissues were fixed in 4% paraformaldehyde (PFA) for histology.
Microarray analysis.
For microarray analysis, all samples were prepared and processed by the Genomics Core Facility at MSKCC. RNA was isolated using Trizol (Invitrogen) and the quality was assessed on an Agilent Bioanalyzer. Total RNA was reverse transcribed and labelled using the Genechip 3 IVT Express Kit (Affymetrix). The resulting cRNA was hybridized to HuMu ProtIn chips (Affymetrix). All bioinformatics analyses were completed in R using the Bioconductor suite 52 . The 'affy' package 53 was used for robust multi-array average normalization followed by quantile normalization. Mouse and human samples and probes were normalized separately. With the exception of the cross-species scatter plots, all subsequent bioinformatics analyses regarded the tumour and stroma separately.
The 'limma' package 54 was used to identify differentially expressed genes, defined by a fold-change cutoff of ±2 and a false discovery rate of 10%. Tissue-specific genes were identified by the intersection of pairwise comparisons: for example, lung stroma-specific genes were identified by the intersection of genes significantly enriched in lung versus bone and genes significantly enriched in lung versus brain. Stage-specific genes were identified in a tissue-specific manner comparing early-and late-stage metastases.
Principal component analysis was completed using the covariance matrix in the 'princomp' function in R. Homologues for mouse and human genes were identified using the HomoloGene Database through the NCBI (http://www.ncbi.nlm.nih.gov/ homologene). Homologue pairs were plotted with mouse/stroma tissue-specific, early versus late, fold change on the x axis, and human/tumour tissue-specific, early versus late, fold change on the y axis.
External data sets and survival analysis.
For gene expression analysis of mouse endothelial cells, raw data from GSE47067 (ref. 34) were imported into R and normalized as above. For patient analysis, normalized gene expression data were downloaded from the GEO (GSE12276; ref. 20) . Each gene was mean centred and scaled by standard deviation. Patients were split into tertiles (lower 33%, middle 33%, upper 33%) of CTSS gene expression for Kaplan-Meier survival analysis. The scaled, continuous CTSS gene expression was used for hazard ratio calculation. Similar analyses were completed for genes in Supplementary Fig. 4c -e. Survival analysis was completed using the 'survival' package in R (ref. 55). Hazard ratios were determined utilizing the 'coxph' function from the 'survival' package. Nominal P values are reported for hazard ratio significance in Supplementary Table 2 with a significance cutoff of 0.05 used to identify genes significantly associated with metastasis-free survival. P values were generated using the log-rank statistic for Kaplan-Meier analysis and Wald's test for the hazard ratio analysis.
Clinical samples. Primary breast tumours and brain metastases were provided by E.B., P.K.B. and W.C.H. This research was approved by MSKCC Institutional Review Board (IRB) protocol 06-107 and Dana-Farber/Harvard Cancer Center (DF/HCC) protocol 10-454. All participants provided written consent. Information about the clinical samples can be found in Supplementary Table 3 .
Generation of CTSS KD lines.
Five shRNA sequences targeting CTSS were obtained from the RNAi Codex and RNAi Consortium. shRNA sequences were inserted into the targeting hairpin sequence for the pRetroSuper vector. Correct insertion into the vector was verified by digestion and sequencing of the vector. Plasmids with the correct shRNA targeting sequence were transfected into H29 viral packaging cells. Viral particles were concentrated from the H29 cell supernatant, added to the target cells in the presence of Polybrene and cells were selected with puromycin. The following shRNA sequences were tested for their KD efficiency: CTSS-1 shRNA, 5 -CTAAATTAACCTAAACGTA-3 ; CTSS-2 shRNA, 5 -CAGAGAAATATCACATATA-3 ; CTSS-3 shRNA, 5 -GATAAAGTTTGCTAAG TAA-3 ; CTSS-4 shRNA, 5 -CTAAATTAACCTAAACGT-3 ; and CTSS-5 shRNA, 5 -CTTTCCAGTACATCATTGA-3 . CTSS-3 shRNA was used for subsequent experiments to target CTSS with 90% KD efficiency. A non-targeting shRNA (5 -CGCCATAAATATAACTTTA-3 ) was used as a control.
Targeting tumour-and stroma-derived cathepsin S in vivo. Br-M cells (1 × 10 4 cells; Br-M CTSS KD or Br-M Ctrl) were inoculated into the left ventricle of 6-8week-old female athymic/nude or Ctss KO athymic/nude mice. Metastasis formation was monitored once weekly by BLI using a Xenogen IVIS-200 Optical In Vivo Imaging System to determine metastasis incidence in the four experimental groups shown in the table in Fig. 4b . Lesions that reached the cutoff of 1 × 10 6 photons s −1 in a defined region in the head area were scored positively for brain metastasis in the incidence curve presented in Fig. 4b . In addition, numerical values of the increase in BLI intensity present the kinetics of tumour progression ( Supplementary Fig. 7a ). An independent cohort of mice was injected with Br-M cells as described above and euthanized at day 35 after tumour cell inoculation for subsequent analysis of proliferation, apoptosis, angiogenesis and metastatic outgrowth.
For in vivo extravasation experiments, athymic/nude or Ctss KO athymic/nude mice were inoculated with 5 × 10 5 Br-M Ctrl or Br-M CTSS KD cells. BLI intensity was monitored at 0 h, 24 h and 48 h after tumour cell inoculation and the BLI intensity was plotted relative to the BLI intensity immediately after tumour cell inoculation (0 h time point). Analyses of BLI intensity were performed blinded to the group allocation. No statistical method was used to predetermine sample size.
Identification of cathepsin S inhibitor VBY-999. VBY-999 was provided by
Virobay and is part of an extensive structure-based drug discovery program. VBY-999 is a covalent reversible inhibitor with an electrophilic nitrile warhead. The detailed chemical synthesis and structure of compounds in the structural series including VBY-999 can be found in issued US Patent 7,547,701. Recombinant purified human and mouse cathepsin S were used to assess potency of VBY-999 and determine inhibition constants. Activity on the peptide substrate Z-Leu-Arg-AMC was determined in vitro by measuring hydrolysis of the substrate with spectrofluorimetric quantification of AMC. VBY-999 was preincubated with cathepsin S for 15 min at room temperature (25 • C) after which the substrate was added to initiate the 30 min reaction. Assay incubation buffer included 25 mM CH 3 COONa, pH 4.5, 2.5 mM dithiothreitol (DTT) and 0.05 M NaCl. Appropriate reaction conditions and peptide substrates for other cysteine and serine proteases were utilized to screen for selectivity of VBY-999 for cathepsin S. VBY-999 has an inhibition constant K i(app) = 290 pM on the purified human cathepsin S enzyme, and >3,000-fold selectivity versus the related cathepsins K, L, B and F. Potency on the closely related cathepsins K, L and F was K i(app) ≥ 3 µM, with potency on cathepsin B K i(app) = 700 nM. Potency on mouse cathepsin S enzyme was verified on mouse cathepsin S purified enzyme. VBY-999 has an inhibition constant K i(app) = 690 pM on mouse cathepsin S. No measurable inhibition was detected for any other cysteine, serine or aspartyl proteases tested.
VBY-999 inhibitor preclinical trial. For administration to mice, VBY-999 was formulated in a nanoparticle-based suspension formulation and further diluted in 5% dextrose in water (D5W) at a concentration of 10 mg ml −1 . Subcutaneous dosing of VBY-999 provided a dosing formulation and route that allowed high and sustained plasma concentrations of the drug to be achieved, which was confirmed using a bioanalytical LC-MS/MS method after 2 and 7 days of treatment (Fig. 8b) . This results in full inhibition of the enzyme target for the duration of the trial, following once-daily dosing. To determine whether VBY-999 had sufficient penetration of the CNS to be available for cathepsin S inhibition in the brain and at the blood-brain barrier (BBB), and to confirm that concentrations in the brain remain stable throughout the duration of the trial, VBY-999 concentration was determined by LC-MS/MS at day 2, day 7 and day 37 after treatment initiation (Fig. 8b) . These data indicate that VBY-999 levels in the plasma and brain were significantly above the required concentration for target inhibition at the time of tumour cell inoculation and remain stable throughout the 37-day treatment schedule at a level sufficiently greater than the enzyme inhibition constant, and are thus expected to effectively inhibit cathepsin S activity. For the prevention trials, mice were randomly assigned into vehicle and VBY-999 treatment groups and treatment was started two days before tumour cell inoculation (d = −2). Mice were dosed with 100 mg kg −1 VBY-999 or vehicle (D5W) by subcutaneous injection once daily. At day 0, athymic/nude mice were inoculated with 1 × 10 4 Br-M Ctrl cells or 1 × 10 5 Bo-M Ctrl cells. Metastasis formation was monitored every fifth day by bioluminescence imaging using a Xenogen IVIS-200 Optical In Vivo Imaging System during the trial period from day 0 to day 35 after tumour cell inoculation. For the Bo-M trial, mice were subjected to X-ray analysis at day 35 after tumour cell inoculation using a SPECT-CT scanner (X-SPECT). For the regression trial, mice were stratified into vehicle and VBY-999 treatment groups at day 27 after tumour cell inoculation to achieve equal average BLI intensity at the time of treatment start at day 28. Mice were dosed daily with either vehicle or VBY-999 (100 mg kg −1 ) for 7 days and metastasis growth was monitored by BLI imaging at day 32 and day 35. Analyses of BLI intensity were performed blinded to the group allocation. No statistical method was used to predetermine sample size.
RNA isolation, cDNA synthesis and quantitative real-time PCR. RNA was isolated with Trizol, DNase treated, and 0.2 µg of RNA was used for cDNA synthesis. Details about the Taqman assays can be found in Supplementary Table 4 . All species-specific Taqman assays were chosen on the basis of their location in the mRNA sequence that allows for maximal discrimination between mouse and human transcripts. For each Taqman assay, species specificity was tested by qPCR using mouse or human samples as controls.
Collection of conditioned media, protein isolation and western blotting.
Conditioned medium from Br-M cell lines was generated by incubating confluent cell layers in serum-free DMEM media for 24 h. Collected conditioned medium was passed through 0.22 µm filters to remove cellular debris. For western blotting, conditioned medium was concentrated by centrifugation in Centrifugal Filter Units (Millipore). Proteins from cells or snap-frozen tissue were isolated through lysis or homogenization in RIPA lysis buffer (Pierce) with ×1 complete Mini protease inhibitor cocktail (Roche). Membranes were probed with antibodies as indicated in Supplementary Table 5 and detected with HRP-conjugated secondary antibodies using chemoluminescence detection (Millipore). Bands from western blots were quantified in the dynamic range using the gel analysis module in ImageJ software.
Generation of Serpina3n antibody. Peptides targeting murine Serpina3n were determined through alignment of the protein sequence for Serpina3n against mouse Serpin a3 family members, Serpina3b, c, f, g, k and m, as well as human SERPINA3. From this alignment, divergent regions were located and peptides were chosen that corresponded to regions 373-396 (a3n-no1), 225-248 (a3n-no2) and 398-418 (a3n-no3) of Serpina3n. Ten to fourteen milligrams of each peptide was synthesized by the Pocono Rabbit Farm and Laboratory, with 2 mg of each peptide conjugated to KLH and 2 mg of each peptide conjugated to BSA. The KLH-conjugated peptides were used to generate an immune response in Armenian hamsters and BALB/c mice by the Monoclonal Antibody Core Facility at MSKCC. Serum from hamsters and mice was tested through ELISA using the BSA-conjugated peptides in Nunc Maxisorp ELISA plates. The best responding hamster to all three peptides was used for fusion, and positive colonies were screened by ELISA and for response to each peptide. Clones were screened by immunohistochemistry and immunofluorescence for ability to recognize murine Serpina3n in mouse tissue, and colony 13H5 (which responded to peptide a3n-no1) was selected for subcloning.
Immunocytochemistry. For immunocytochemistry, cells were cultured on glass coverslips and fixed in 4% PFA in 0.1 M phosphate buffer for 20 min at room temperature. Cells were permeabilized in PBS with 0.25% Triton X-100 for 10 min. Cells were blocked in 0.5% PNB (phosphate-NaCl buffer) in PBS for at least 1 h at room temperature, followed by incubation with goat anti-human CTSS primary antibody diluted 1:100 in 0.25% PNB overnight at 4 • C. Donkey anti-goat Alexa568 secondary antibody (Molecular Probes) was used at a dilution of 1:500 in 0.25% PNB for 1 h at room temperature.
Tissue preparation and immunostaining. Tissue for frozen histology was fixed in 4% PFA overnight, and brain and lung samples were subsequently transferred into 30% sucrose until the tissue was fully equilibrated. Bone samples were decalcified in 0.5 M EDTA, pH 8.0 for 14 days. All tissues were then embedded in OCT (Tissue-Tek) and 10 µm or 20 µm cryostat tissue sections were used for all subsequent analyses. For immunofluorescence, frozen sections were thawed and dried at room temperature and rehydrated. For the standard staining protocol, tissue sections were blocked in 0.5% PNB in PBS for at least 1 h at room temperature, followed by incubation with primary antibody in 0.25% PNB overnight at 4 • C. Primary antibody information and dilutions are listed in Supplementary Table 5 . Fluorophoreconjugated secondary antibodies (Molecular Probes) were used at a dilution of 1:500 in 0.25% PNB for 1 h at room temperature.
Paraffin-embedded sections were processed using a Ventana automated staining device. The automated deparaffinization/rehydration, citrate buffer-based antigen retrieval, and blocking of unspecific protein binding and endogenous peroxidase was followed by incubation with mouse anti-human CD68 (Dako) primary antibody and goat anti-human CTSS (R&D Systems) or mouse anti-human CK (Dako) and goat anti-human CTSS (R&D Systems) overnight at 4 • C. Sections were incubated with donkey-anti mouse HRP-labelled secondary antibody (Jackson Immunoresearch, 1:200) in 0.25% PNB buffer in PBS for 1.5 h followed by incubation with Alexa488labelled tyramide (Invitrogen) at a 1:200 dilution in amplification buffer for 8 min. Following the signal amplification reaction, donkey anti-goat Alexa568 (Molecular Probes) was used at a dilution of 1:500 in 0.25% PNB for 1 h at room temperature. Frozen sections that were used for Jam-B, Cldn3 and Ocln staining were processed using a Ventana automated staining device. The automated rehydration, citrate buffer-based antigen retrieval, and blocking of unspecific protein binding and endogenous peroxidase steps were followed by incubation with rat anti-mouse Jam-B (Pierce) primary antibody and goat anti-mouse Cd31 (R&D Systems), rabbit anti-mouse Cldn3 (Invitrogen) and goat anti-mouse Cd31, or rabbit anti-mouse Ocln (Invitrogen) and goat anti-mouse Cd31 overnight at 4 • C. Sections were incubated with donkey anti-rat or donkey anti-rabbit biotin-labelled secondary antibody (Vector, 1:200) in PBS + 0.03% Tween for 1.5 h followed by incubation with streptavidin-Cy5 (Invitrogen, 1:200) PBS + 0.03% Tween for 20 min. Donkey anti-goat Alexa568 (Molecular Probes) was used at a dilution of 1:500 in 0.25% PNB for 1 h at room temperature. Apoptotic cells were stained through terminal dUTP nick end labelling (TUNEL) following the manufacturer's instructions (Trevigen), with the modification of using streptavidin-Cy5 (Invitrogen; 1:200) instead of streptavidin-FITC.
Microscopy and image analysis. Tissue sections and cells on coverslips were
visualized under a Carl Zeiss Axioimager Z1 microscope equipped with an ApoTome.2 and a TissueGnostics stage to allow for automated image acquisition. The analyses of proliferation and apoptosis were performed using TissueQuest analysis software (TissueGnostics) as previously described 56 . All parameters of metastatic outgrowth and angiogenesis were quantified using MetaMorph software (Molecular Devices). Briefly, vasculature was visualized by Texas red lectin (Vector Laboratories) injections or by staining of the endothelial cell marker CD34. Tumour cells were detected by their expression of the GFP reporter. The area covered by CD34 and GFP staining was quantified. To determine the number of tumour cells that are present within an area of 1 to >4 average tumour cell diameters, the blood vessel area was dilated by 1-4 average tumour cell diameters with an increment of 1 tumour cell diameter and the number of tumour cells in each area was determined. Tumour cells that were localized outside an area of 4 average tumour cell diameter were defined as >4 tumour cell diameter away from CD34 + blood vessels as illustrated in Fig. 5b . Vessel density was quantified as the area covered by Texas red lectin relative to the area covered by DAPI.
To histologically quantify the percentage of intravascular, extravasating or extravasated tumour cells (Fig. 6c ), brain sections were stained for TUNEL + cells to exclude non-viable tumour cells from the analysis. Brain sections were automatically acquired using TissueQuest software (TissueGnostics), which used a z-stack (5 images above and below the focal plane, 0.3 µm steps, ×20 objective) to generate a maximal intensity projection image of each acquired brain area. Tumour cells were detected by Cell Tracker green (Invitrogen) and vasculature was visualized by Texas red lectin (Vector Laboratories) injections. Tumour cells were counted manually and their localization relative to the vasculature was determined.
For analysis of human samples, 5-10 fields of view were acquired using a ×20 objective (total magnification ×200) and a Zeiss Apotome to ensure that cells were in the same optical section. The number of CK + tumour cells and CD68 + macrophages, and their relative CTSS intensities (CTSS index), was evaluated using CellProfiler 2.0 software. A CellProfiler module was generated that allowed for the detection of tumour cells and macrophages based on their DAPI and CK signal, or DAPI and CD68 signal, respectively. The CTSS signal intensity was measured in the whole cell population (DAPI + ) and associated with a specific cell type (macrophages or tumour cells), and the proportion of CTSS signal associated with CK + tumour cells or CD68 + macrophages was calculated relative to the overall CTSS signal intensity in all DAPI + cells. Analyses of histological assessment were performed blinded to the group allocation.
Measurement of vessel permeability. Athymic/nude mice (6-8-week-old) were injected with Evan's blue dye (30 mg kg −1 ) into the tail vein. Thirty minutes after injection, mice were anaesthetized and perfused with acidified fixative (1% PFA in 0.05 mM citrate buffer, pH 3.5). Thirty milligrams of brain tissue was incubated in 500 µl formamide (Sigma) to extract Evan's blue at 60 • C overnight. Absorbance was measured at 610 and 740 nm on a spectraMax 340pc plate reader (Molecular Devices).
In vitro BBB transmigration assays. In vitro BBB transmigration assays were performed as previously described 29 . The artificial BBB was formed with either HUVECs or HBMECs (20,000 cells per well) in co-culture with HA cells (100,000 cells per well) for 3 days on Transwell inserts with 3 µm fluoroblok membranes. Cell Tracker green (CMFDA)-labelled Br-M Ctrl or Br-M CTSS KD cells (20,000 cells per well) were allowed to transmigrate for 18 h through the artificial BBB towards a FBS gradient, in the presence or absence of VBY-999 (10 µM). Tumour cell transmigration through empty inserts (coated with gelatin and poly-L-lysine) or inserts coated with HUVECs, HBMECs or HAs alone was used to determine the baseline migratory potential and the contribution of the single cell types to BBB formation. The number of transmigrated tumour cells was quantified by analysing 200 fields of view that were acquired with a ×20 objective (×200 total magnification) using TissueQuest analysis software (TissueGnostics). Analysis was performed blinded to the group allocation.
In vitro and cell-based cleavage assays. Recombinant inactive CTSS was obtained from R&D Systems. CTSS was activated at 50 ng µl in 50 mM sodium acetate, 5 mM DTT, 0.25 M NaCl (pH 4.5) for 1.5 h at 37 • C. For the in vitro cleavage reaction, activated CTSS was incubated with recombinant proteins in the presence or absence of the cathepsin S inhibitor VBY-999 (10 µM) for 0, 10 or 20 min in 50 mM sodium acetate, 5 mM DTT, 0.25 M NaCl at pH 4.5 and pH 6.0. Details about the recombinant proteins used in the in vitro cleavage assay can be found in Supplementary Table 6 . The cleavage reaction was stopped by adding SDS sample buffer and reducing agent (Invitrogen) and the samples were boiled at 95 • C for 5 min. Aliquots were subjected to western blot analysis as described above. Information about the antibodies can be found in Supplementary Table 5 . All experiments were repeated independently at least three times.
For cell-based cleavage assays, HBMECs were grown to 100% confluence in a 10 cm plate. Conditioned medium from Br-M cells was collected as described above. Two hundred microlitres of concentrated Br-M-conditioned media (collected from two 10 cm plates of confluent Br-M cells) was diluted in 6.5 ml PBS pH 6.0 + 0.05 mM DTT for each 10 cm plate of HBMECs. The cleavage reaction was performed in the presence or absence of VBY-999 (10 µM) for 0 h, 2 h and 4 h. PBS pH 6.0 + 0.05 mM DTT was used as a control. The supernatant from HBMEC cell layers was collected after the indicated time points, concentrated and subjected to western blot analysis as described above.
Proliferation assays. Cell growth rate was determined using an MTT cell proliferation kit (Roche). Briefly, cells were plated in triplicate in 96-well plates (2.5 × 10 3 for Br-M Ctrl and Br-M CTSS KD cells) in the presence or absence of 0.1-100 µm VBY-999. Ten microlitres of MTT labelling reagent was added to each well and then incubated for 4 h at 37 • C, followed by the addition of 100 µl MTT solubilization reagent overnight. Absorbance was measured at 595 nm and 750 nm on a spectraMax 340pc plate reader (Molecular Devices).
